UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 21, 2016
ENDO INTERNATIONAL PLC
(Exact Name of Registrant as Specified in Its Charter)
| | | | |
| Ireland | | 001-36326 | | 68-0683755 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | |
First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland | | Not Applicable |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code 011-353-1-268-2000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01 | Regulation FD Disclosure. |
On March 21, 2016, Endo International plc (“Endo”) issued a press release and announced that it has posted an informational Frequently Asked Questions & Answers (Q&A) document (“Investor FAQ”) regarding the approval by the U.S. Food and Drug Administration of a competitor’s generic version of Voltaren® Gel (diclofenac sodium topical gel) 1%. The Investor FAQ is posted on the Investor Relations section of Endo’s website atwww.endo.com. A copy of the press release and Investor FAQ are attached hereto as Exhibits 99.1 and 99.2 respectively.
The information furnished under this item 7.01, including the exhibits, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities arising under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| | |
| |
| 99.1 | | Press Release of Endo International plc dated March 21, 2016 |
| |
| 99.2 | | Investor FAQ dated March 21, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| | |
| ENDO INTERNATIONAL PLC |
| |
| By: | | /s/ Matthew J. Maletta |
| Name: | | Matthew J. Maletta |
| Title: | | Executive Vice President, |
| | Chief Legal Officer |
Dated: March 21, 2016
INDEX TO EXHIBITS
| | |
Exhibit Number | | Description |
| |
| 99.1 | | Press Release of Endo International plc dated March 21, 2016 |
| |
| 99.2 | | Investor FAQ dated March 21, 2016 |
